- Home
- CUBA vs MAIA Comparison
CUBA vs MAIA Comparison
Compare CUBA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBA
- MAIA
- Stock Information
- Founded
- CUBA 1992
- MAIA 2018
- Country
- CUBA United States
- MAIA United States
- Employees
- CUBA N/A
- MAIA N/A
- Industry
- CUBA Investment Managers
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CUBA Finance
- MAIA Health Care
- Exchange
- CUBA Nasdaq
- MAIA Nasdaq
- Market Cap
- CUBA 39.0M
- MAIA 46.7M
- IPO Year
- CUBA N/A
- MAIA 2022
- Fundamental
- Price
- CUBA $2.43
- MAIA $1.79
- Analyst Decision
- CUBA
- MAIA
- Analyst Count
- CUBA 0
- MAIA 0
- Target Price
- CUBA N/A
- MAIA N/A
- AVG Volume (30 Days)
- CUBA 93.9K
- MAIA 273.5K
- Earning Date
- CUBA 01-01-0001
- MAIA 05-09-2025
- Dividend Yield
- CUBA 20.83%
- MAIA N/A
- EPS Growth
- CUBA N/A
- MAIA N/A
- EPS
- CUBA N/A
- MAIA N/A
- Revenue
- CUBA N/A
- MAIA N/A
- Revenue This Year
- CUBA N/A
- MAIA N/A
- Revenue Next Year
- CUBA N/A
- MAIA N/A
- P/E Ratio
- CUBA N/A
- MAIA N/A
- Revenue Growth
- CUBA N/A
- MAIA N/A
- 52 Week Low
- CUBA $2.25
- MAIA $1.40
- 52 Week High
- CUBA $4.14
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- CUBA 40.23
- MAIA 47.79
- Support Level
- CUBA $2.35
- MAIA $1.71
- Resistance Level
- CUBA $2.53
- MAIA $1.85
- Average True Range (ATR)
- CUBA 0.09
- MAIA 0.13
- MACD
- CUBA -0.02
- MAIA -0.02
- Stochastic Oscillator
- CUBA 17.78
- MAIA 25.64
About CUBA Herzfeld Caribbean Basin Fund Inc. (The)
Herzfeld Caribbean Basin Fund Inc operates as a closed-end management investment company. The company's investment objective is to obtain long-term capital appreciation. The firm offers customized discretionary account management and fund management services to individual and institutional investors. The fund invests in equity and equity-linked securities of public and private companies, including United States-based companies, whose securities are traded principally on a stock exchange in a Caribbean Basin Country. The fund's revenue source is through the dividends it receives. Its investments are geographically allocated in the United States followed by Mexico, Puerto Rico, and other countries.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.